{"protocolSection":{"identificationModule":{"nctId":"NCT00191139","nctIdAliases":["NCT00074217"],"orgStudyIdInfo":{"id":"4697"},"secondaryIdInfos":[{"id":"B9E-US-S182","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)","officialTitle":"A Randomized Study of Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation Therapy in Stage III Unresectable NSCLC"},"statusModule":{"statusVerifiedDate":"2010-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2003-03"},"primaryCompletionDateStruct":{"date":"2008-11","type":"ACTUAL"},"completionDateStruct":{"date":"2009-02","type":"ACTUAL"},"studyFirstSubmitDate":"2005-09-12","studyFirstSubmitQcDate":"2005-09-12","studyFirstPostDateStruct":{"date":"2005-09-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-11-20","resultsFirstSubmitQcDate":"2009-11-20","resultsFirstPostDateStruct":{"date":"2009-12-25","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-02-04","lastUpdatePostDateStruct":{"date":"2010-02-17","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":64,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Gemcitabine","type":"EXPERIMENTAL","interventionNames":["Drug: gemcitabine","Drug: cisplatin","Drug: etoposide","Radiation: radiation therapy"]},{"label":"Gemcitabine plus Docetaxel","type":"EXPERIMENTAL","interventionNames":["Drug: gemcitabine","Drug: docetaxel","Drug: cisplatin","Drug: etoposide","Radiation: radiation therapy"]}],"interventions":[{"type":"DRUG","name":"gemcitabine","description":"After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.","armGroupLabels":["Gemcitabine","Gemcitabine plus Docetaxel"],"otherNames":["LY188011","Gemzar"]},{"type":"DRUG","name":"docetaxel","description":"Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.","armGroupLabels":["Gemcitabine plus Docetaxel"],"otherNames":["Taxotere"]},{"type":"DRUG","name":"cisplatin","description":"As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)","armGroupLabels":["Gemcitabine","Gemcitabine plus Docetaxel"],"otherNames":["Platinol","Platinol-AQ","CDDP"]},{"type":"DRUG","name":"etoposide","description":"As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)","armGroupLabels":["Gemcitabine","Gemcitabine plus Docetaxel"],"otherNames":["Toposar®","VePesid®","Etopophos®","VP-16","Etoposide phosphate"]},{"type":"RADIATION","name":"radiation therapy","description":"In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks","armGroupLabels":["Gemcitabine","Gemcitabine plus Docetaxel"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"2-Year Survival","description":"Percentage of participants alive at 2 years.","timeFrame":"2 years"}],"secondaryOutcomes":[{"measure":"Number of Patients With Overall Tumor Response","description":"Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) =30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) =20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. The total number of CRs plus PRs equals overall response rate (ORR).","timeFrame":"randomization and every 3 months up to 2 years of post-study followup"},{"measure":"Progression-Free Survival","description":"Defined as the time from randomization into consolidation treatment to the first date of documented disease progression or death. Progression-free survival time was censored at the date of the last follow-up visit at which disease was assessed for patients who were still alive and who had not progressed.","timeFrame":"baseline to measured progressive disease up to 2057 days"},{"measure":"Overall Survival","description":"Overall survival is the duration from enrollment to death from any cause. For patients who are alive, overall survival is censored at the last contact.","timeFrame":"baseline to date of death from any cause up to 2057 days"},{"measure":"Lung Cancer Symptom Scale (LCSS) Assessment Post-randomization","description":"LCSS measures physical \\& functional dimensions. The patient scale contains 9 items, 3 summation \\& 6 symptom items. Each item is marked on a visual analog scale (0=low; 100=high). The mean of the 6 symptoms is used to calculate the average symptom burden index (ASBI). Improved=mean ASBI assessments from any 2 consecutive improved post-randomization assessments was at least 0.5 standard deviation (SD) below pre-randomization ASBI; worse=mean ASBI from any 2 consecutive post-randomization assessments was at least 0.5 SD above pre-randomization ASBI; stable=criteria for improved/worse not met.","timeFrame":"baseline to 3 months after last dose of study treatment (three 21-day cycles)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* histologic or cytologic proof of single primary non-small cell lung cancer\n* No prior chemotherapy or radiation therapy\n* no prior malignancy\n\nExclusion Criteria:\n\n* pregnancy or breastfeeding\n* serious concomitant systemic disorder\n* unintentional weight loss greater than 10%","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Denver","state":"Colorado","zip":"80218","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"South Bend","state":"Indiana","zip":"46601","country":"United States","geoPoint":{"lat":41.68338,"lon":-86.25001}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Baltimore","state":"Maryland","zip":"21237","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Kalamazoo","state":"Michigan","zip":"49048","country":"United States","geoPoint":{"lat":42.29171,"lon":-85.58723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Kansas City","state":"Missouri","zip":"64128","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Portland","state":"Oregon","zip":"97213","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Philadelphia","state":"Pennsylvania","zip":"19111","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Memphis","state":"Tennessee","zip":"38120","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Rosario","zip":"2000","country":"Argentina","geoPoint":{"lat":-32.94682,"lon":-60.63932}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Beijing","zip":"100021","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Chengdu","zip":"610041","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Seoul","zip":"138-736","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph","city":"Suwon","zip":"442-723","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Gemcitabine","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles"},{"id":"FG001","title":"Gemcitabine Plus Docetaxel","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles; docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"32"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"12"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Disease Progression","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Gemcitabine","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles"},{"id":"BG001","title":"Gemcitabine Plus Docetaxel","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles; docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"64"}]}],"measures":[{"title":"Age Continuous","paramType":"MEDIAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.5","spread":"7.31"},{"groupId":"BG001","value":"59.5","spread":"9.61"},{"groupId":"BG002","value":"59.5","spread":"8.48"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"53"}]}]}]},{"title":"Race/Ethnicity, Customized","description":"breakdown of participants by ethnic origin","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"37"}]}]},{"title":"Black","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"23"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"38"}]}]},{"title":"Argentina","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"China","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"17"}]}]},{"title":"Korea, Republic of","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}]}]},{"title":"Eastern Oncology Cooperative Group (ECOG) Performance Status","description":"Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).","paramType":"NUMBER","unitOfMeasure":"units on a scale","classes":[{"title":"0 - Fully Active","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"26"}]}]},{"title":"1 - Ambulatory, Restricted Strenuous Activity","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"37"}]}]},{"title":"2 - Ambulatory, No Work Activities","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"2-Year Survival","description":"Percentage of participants alive at 2 years.","populationDescription":"Intention to treat (ITT) population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"2 years","groups":[{"id":"OG000","title":"Gemcitabine","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles"},{"id":"OG001","title":"Gemcitabine Plus Docetaxel","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles; docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6"},{"groupId":"OG001","value":"55.7"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"normal approximation","statisticalComment":"Count the number of surviving participants at each time interval to get survival rates.","paramType":"survival rate","paramValue":"40.6","ciPctValue":"95","ciLowerLimit":"23.8","ciUpperLimit":"56.8"},{"groupIds":["OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"normal approximation","statisticalComment":"Count the number of surviving participants at each time interval to get survival rates.","paramType":"survival rate","paramValue":"55.7","ciPctValue":"95","ciLowerLimit":"36.8","ciUpperLimit":"70.9"}]},{"type":"SECONDARY","title":"Number of Patients With Overall Tumor Response","description":"Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) =30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) =20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. The total number of CRs plus PRs equals overall response rate (ORR).","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"randomization and every 3 months up to 2 years of post-study followup","groups":[{"id":"OG000","title":"Gemcitabine","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles"},{"id":"OG001","title":"Gemcitabine Plus Docetaxel","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles; docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"27"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"normal approximation","paramType":"Response Rate","paramValue":"75","ciPctValue":"95","ciLowerLimit":"56.6","ciUpperLimit":"88.5"},{"groupIds":["OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"Normal approximation","paramType":"Response rate","paramValue":"84.4","ciPctValue":"95","ciLowerLimit":"67.2","ciUpperLimit":"94.7"}]},{"type":"SECONDARY","title":"Progression-Free Survival","description":"Defined as the time from randomization into consolidation treatment to the first date of documented disease progression or death. Progression-free survival time was censored at the date of the last follow-up visit at which disease was assessed for patients who were still alive and who had not progressed.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"baseline to measured progressive disease up to 2057 days","groups":[{"id":"OG000","title":"Gemcitabine","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles"},{"id":"OG001","title":"Gemcitabine Plus Docetaxel","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles; docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162.5","lowerLimit":"82.0","upperLimit":"239.0"},{"groupId":"OG001","value":"408.0","lowerLimit":"141.0","upperLimit":"708.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.08","statisticalMethod":"Log Rank","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival is the duration from enrollment to death from any cause. For patients who are alive, overall survival is censored at the last contact.","populationDescription":"ITT population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"baseline to date of death from any cause up to 2057 days","groups":[{"id":"OG000","title":"Gemcitabine","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles"},{"id":"OG001","title":"Gemcitabine Plus Docetaxel","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles; docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"492.5","lowerLimit":"299.0","upperLimit":"1034.0"},{"groupId":"OG001","value":"899.0","lowerLimit":"498.0","upperLimit":"1583.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.38","statisticalMethod":"Log Rank","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Lung Cancer Symptom Scale (LCSS) Assessment Post-randomization","description":"LCSS measures physical \\& functional dimensions. The patient scale contains 9 items, 3 summation \\& 6 symptom items. Each item is marked on a visual analog scale (0=low; 100=high). The mean of the 6 symptoms is used to calculate the average symptom burden index (ASBI). Improved=mean ASBI assessments from any 2 consecutive improved post-randomization assessments was at least 0.5 standard deviation (SD) below pre-randomization ASBI; worse=mean ASBI from any 2 consecutive post-randomization assessments was at least 0.5 SD above pre-randomization ASBI; stable=criteria for improved/worse not met.","populationDescription":"as-treated population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"baseline to 3 months after last dose of study treatment (three 21-day cycles)","groups":[{"id":"OG000","title":"Gemcitabine","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles"},{"id":"OG001","title":"Gemcitabine Plus Docetaxel","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles; docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"}]}],"classes":[{"title":"Improvement","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}]},{"title":"Stable","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}]},{"title":"Worse","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Gemcitabine","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles","seriousNumAffected":13,"seriousNumAtRisk":32,"otherNumAffected":32,"otherNumAtRisk":32},{"id":"EG001","title":"Gemcitabine Plus Docetaxel","description":"Consolidation Treatment: gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles; docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.","seriousNumAffected":18,"seriousNumAtRisk":32,"otherNumAffected":32,"otherNumAtRisk":32}],"seriousEvents":[{"term":"Anaemia NOS","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":8,"numAffected":4,"numAtRisk":32}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Leukopenia NOS","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":7,"numAffected":1,"numAtRisk":32}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":6,"numAffected":2,"numAtRisk":32}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Cardiac failure NOS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Diarrhoea NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Diverticulitis NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Gastrointestinal haemorrhage NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Oesophagitis NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":32}]},{"term":"Vomiting NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":32}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Death NOS","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Candidal infection NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Lung infection NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Pneumonia NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":32},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":32}]},{"term":"Sepsis NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":32}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Convulsions NOS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Alveolitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Chronic obstructive airways disease exacerbated","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Pneumonitis NOS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":32}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Face oedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Vena cava thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]}],"otherEvents":[{"term":"Anaemia NOS","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":18,"numAtRisk":32},{"groupId":"EG001","numEvents":63,"numAffected":24,"numAtRisk":32}]},{"term":"Erythropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":32}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":32}]},{"term":"Granulocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":32}]},{"term":"Leukopenia NOS","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":12,"numAtRisk":32},{"groupId":"EG001","numEvents":41,"numAffected":13,"numAtRisk":32}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":32},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":32}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":93,"numAffected":19,"numAtRisk":32},{"groupId":"EG001","numEvents":73,"numAffected":23,"numAtRisk":32}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":9,"numAtRisk":32},{"groupId":"EG001","numEvents":33,"numAffected":13,"numAtRisk":32}]},{"term":"Tachycardia NOS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":32},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":32}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":32}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":32}]},{"term":"Abdominal pain NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":32}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":32}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":13,"numAtRisk":32},{"groupId":"EG001","numEvents":25,"numAffected":14,"numAtRisk":32}]},{"term":"Diarrhoea NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":9,"numAtRisk":32},{"groupId":"EG001","numEvents":22,"numAffected":16,"numAtRisk":32}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":32},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":32}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":11,"numAtRisk":32},{"groupId":"EG001","numEvents":19,"numAffected":13,"numAtRisk":32}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":32}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":54,"numAffected":23,"numAtRisk":32},{"groupId":"EG001","numEvents":62,"numAffected":28,"numAtRisk":32}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":32}]},{"term":"Oesophagitis NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":6,"numAtRisk":32},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":32}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":32}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Vomiting NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":17,"numAtRisk":32},{"groupId":"EG001","numEvents":47,"numAffected":22,"numAtRisk":32}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":32},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":32}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":32},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":32}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":19,"numAtRisk":32},{"groupId":"EG001","numEvents":59,"numAffected":26,"numAtRisk":32}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":32}]},{"term":"Oedema NOS","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":8,"numAffected":3,"numAtRisk":32}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":32}]},{"term":"Pain NOS","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":32}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":10,"numAtRisk":32},{"groupId":"EG001","numEvents":22,"numAffected":14,"numAtRisk":32}]},{"term":"Rigors","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":32}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":32}]},{"term":"Candidal infection NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Lower respiratory tract infection NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Pneumonia NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Upper respiratory tract infection NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Urinary tract infection NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Dermatitis radiation NOS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":32},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":32}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":32}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":32}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":32}]},{"term":"Sputum increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":32},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":32}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":16,"numAtRisk":32},{"groupId":"EG001","numEvents":31,"numAffected":17,"numAtRisk":32}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":32},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":32}]},{"term":"Hyperglycaemia NOS","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":19,"numAffected":6,"numAtRisk":32}]},{"term":"Hypernatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":7,"numAffected":2,"numAtRisk":32}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":32}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":5,"numAtRisk":32},{"groupId":"EG001","numEvents":9,"numAffected":3,"numAtRisk":32}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":32}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":32}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":32}]},{"term":"Chest wall pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Local swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":32}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":15,"numAffected":11,"numAtRisk":32}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":32},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":32}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":32},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":32}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Peripheral neuropathy NOS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":32}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":32}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":32},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":32}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":17,"numAtRisk":32},{"groupId":"EG001","numEvents":22,"numAffected":16,"numAtRisk":32}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":14,"numAtRisk":32},{"groupId":"EG001","numEvents":26,"numAffected":16,"numAtRisk":32}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":32}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":32}]},{"term":"Hoarseness","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Pharyngolaryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":32},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":32}]},{"term":"Pneumonitis NOS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Pulmonary congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Rales","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Sputum discoloured","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":32},{"groupId":"EG001","numEvents":24,"numAffected":20,"numAtRisk":32}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":32},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":32}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":32}]},{"term":"Rash NOS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":2,"numAtRisk":32},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":32}]},{"term":"Sweating increased","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":32}]},{"term":"Hypotension NOS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":32},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":32}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Brazil"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000093542","term":"Gemcitabine"},{"id":"D000077143","term":"Docetaxel"},{"id":"D002945","term":"Cisplatin"},{"id":"D005047","term":"Etoposide"},{"id":"C061400","term":"etoposide phosphate"},{"id":"D011878","term":"Radiotherapy"}],"ancestors":[{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D011034","term":"Podophyllotoxin"},{"id":"D013764","term":"Tetrahydronaphthalenes"},{"id":"D009281","term":"Naphthalenes"},{"id":"D011084","term":"Polycyclic Aromatic Hydrocarbons"},{"id":"D006841","term":"Hydrocarbons, Aromatic"},{"id":"D011083","term":"Polycyclic Compounds"},{"id":"D005960","term":"Glucosides"},{"id":"D006027","term":"Glycosides"},{"id":"D002241","term":"Carbohydrates"},{"id":"D013812","term":"Therapeutics"}]}},"hasResults":true}